3 Data-Backed Insights from 3,447 Biopharma Deals
What the largest analysis of biopharma licensing economics reveals about phase premiums, therapeutic area pricing, and modality trends.
The Phase 2 Inflection Point
Phase 2 proof-of-concept is the single most valuable inflection point in biopharma deal economics. The Phase 1 to Phase 2 jump delivers a 2.1x increase in median upfront — the largest single-phase multiplier in the entire development lifecycle.
| Phase at Signing | Median Upfront | Median TDV | Upfront % of TDV | n |
|---|---|---|---|---|
| Preclinical | $82M | $888M | 9.7% | 420 |
| Phase 1 | $140M | $1,209M | 11.1% | 350 |
| Phase 2 | $300M | $1,801M | 14.2% | 426 |
| Phase 3 | $678M | $3,500M | 16.8% | 345 |
| Approved | $1,964M | $6,750M | 26.5% | 364 |
Implication for BD teams
If you're negotiating a Phase 1 out-license and the asset has near-term Phase 2 data, a 6-12 month delay could unlock >$150M in additional upfront value. The risk premium compresses sharply at proof-of-concept.
Immunology Commands 4x the Oncology Upfront at Phase 2
The conventional wisdom that oncology commands the highest deal premiums is wrong — at least at Phase 2. Immunology and metabolic deals are being repriced in real-time by TL1A antibodies, oral GLP-1s, and validated $10B+ commercial models.
| Therapeutic Area | Phase 2 Upfront | Phase 3 Upfront | Ph2 → Ph3 Multiple |
|---|---|---|---|
| Metabolic | $1,300M | $4,500M | 3.5x |
| Immunology | $1,250M | $3,200M | 2.6x |
| Neurology | $302M | $838M | 2.8x |
| Oncology | $281M | $714M | 2.5x |
Why this matters
If your pipeline spans multiple TAs, your deal timing strategy should account for these TA-specific premiums. A Phase 2 immunology asset may out-value a Phase 3 oncology asset on upfront alone.
ADC Deals Peaked at $372B in 2023 — Then Normalized
2023 was a once-in-a-generation moment for ADC deal-making, driven by the $43B Pfizer-Seagen acquisition. Deal volume continues to grow, but the era of platform-level mega-deals has given way to focused single-asset licensing.
| Year | ADC Deals | Median TDV | Total Value |
|---|---|---|---|
| 2019 | 17 | $1,339M | $46.2B |
| 2020 | 20 | $2,663M | $136.8B |
| 2021 | 18 | $1,686M | $76.8B |
| 2022 | 25 | $3,302M | $105.1B |
| 2023 | 32 | $5,932M | $371.8B |
| 2024 | 35 | $1,824M | $104.4B |
| 2025* | 17 | $1,598M | $36.7B |
*2025 data through Q3
Despite normalization, ADCs remain the highest-valued modality on upfront:
For ADC licensors
The market has shifted from "acquire the platform" to "license the best asset." Focus positioning on target differentiation, payload novelty, and Phase 2 data quality — that's where the upfront premium lives now.
Run Your Own Deal Benchmark
Model upfronts, milestones, and royalties for any phase, modality, and therapeutic area — powered by 3,447 real transactions.
Data updated daily from SEC filings, press releases, and verified sources.